Laurence Digue

1, Rue Jean Burguet
Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

REFCOR guidelines on the management of olfactory neuroblastoma: A formalized expert consensus.

REFCOR guidelines on the management of olfactory neuroblastoma: A formalized expert consensus.

Journal: European annals of otorhinolaryngology, head and neck diseases

Published: July 13, 2026

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Sinonasal squamous cell carcinoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Journal: European annals of otorhinolaryngology, head and neck diseases

Published: July 06, 2026

Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy.

Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy.

Journal: Cancer treatment and research communications

Published: May 14, 2026

Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy.

Alternative bevacizumab schedule in high-grade gliomas recurrence is associated with reductions in greenhouse gas emissions without loss of clinical efficacy.

Journal: Cancer treatment and research communications

Published: May 14, 2026

REFCOR guidelines for sinonasal adenocarcinoma.

REFCOR guidelines for sinonasal adenocarcinoma.

Journal: European annals of otorhinolaryngology, head and neck diseases

Published: May 09, 2026

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

Journal: European annals of otorhinolaryngology, head and neck diseases

Published: May 09, 2026

Severe oral lichenoid reactions associated with immune checkpoint inhibitors.

Severe oral lichenoid reactions associated with immune checkpoint inhibitors.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 30, 2026

REFCOR guidelines for sinus and nasal cavity cancer.

REFCOR guidelines for sinus and nasal cavity cancer.

Journal: European annals of otorhinolaryngology, head and neck diseases

Published: February 20, 2026

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Journal: Oral oncology

Published: February 20, 2026

Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study.

Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study.

Journal: Cancers

Published: December 23, 2025

Parenting adolescents and young adults (AYA) with cancer: experiences of AYAs and parents of AYAs (with cancer).

Parenting adolescents and young adults (AYA) with cancer: experiences of AYAs and parents of AYAs (with cancer).

Journal: Journal of pediatric nursing

Published: June 29, 2025

Survival rates and prognostic factors of 118 sinonasal sarcomas among adolescents and adults: a national database REFCOR study.

Survival rates and prognostic factors of 118 sinonasal sarcomas among adolescents and adults: a national database REFCOR study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 14, 2025

Showing 1-12 of 46

Last Updated: 09/26/2026